Safety and Efficacy of a Mobiderm Compression Bandage During Intensive Phase of Decongestive Therapy in Patients with Breast Cancer-Related Lymphedema: A Randomized Controlled Trial
Open Access
- 1 February 2023
- journal article
- research article
- Published by SAGE Publications in Lymphatic Research and Biology
- Vol. 21 (1) , 52-59
Abstract
Background: Breast cancer-related lymphedema (BCRL) after primary therapy is a common condition, causing physical and psychological distress. Decongestive lymphedema therapy (DLT) using multi-layered compression bandages is an effective treatment. We conducted a randomized controlled trial evaluating the use of a specific mobilizing bandage (Mobiderm ® ) on lymphedema volume reduction during the intensive phase of DLT. Methods and Results: Fifty female BCRL patients were randomized to receive either conventional multi-layered bandages or mobilizing bandaging by using Mobiderm. Affected limb volume and excess volume were evaluated at baseline (D0) and after 15 days. The primary outcome was change in affected limb volume after adjustment for baseline. Symptom scores were evaluated by visual analogue scale (VAS); safety and tolerability were also assessed. Baseline characteristics were comparable. Affected limb volume reduction was observed in both study groups after 15 days: by 19.0% in the Mobiderm arm and 8.6% in controls (adjusted values). The between-group mean difference in adjusted volume reduction at day 15 was 256 mL (95% confidence interval [CI], 92.5 to 421.3 mL; p = 0.003) favoring Mobiderm. Reductions in excess volume of 57.3% (Mobiderm) and 25.1% (controls) were observed (adjusted values); with between-group mean difference in adjusted excess volume of 220.2 mL (95% CI, 69.3 to 371.3 mL; p = 0.006) favoring Mobiderm. Pain/heaviness VAS scores fell significantly in both groups, with mean reductions of 1.84 (Mobiderm) versus 0.83 (control; p = 0.001). Both regimens were well tolerated. Conclusion: The use of Mobiderm in multilayer compression bandaging shows benefit in lymphedema reduction and in alleviating functional symptoms/pain in patients with BRCL.Keywords
This publication has 26 references indexed in Scilit:
- Impact of body mass index and weight fluctuation on lymphedema risk in patients treated for breast cancerBreast Cancer Research and Treatment, 2013
- Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysisThe Lancet Oncology, 2013
- Erratum to: Lymphedema and breast cancer: a review of the literatureBreast Cancer, 2011
- Body mass index and breast cancer treatment-related lymphedemaSupportive Care in Cancer, 2011
- Study of Incidence of Lymphedema in Indian Patients Undergoing Axillary Dissection for Breast CancerIndian Journal of Surgical Oncology, 2010
- Predictive Factors of Response to Decongestive Therapy in Patients with Breast-Cancer-Related LymphedemaAnnals of Surgical Oncology, 2009
- Lymphedema in Breast Cancer Survivors: Incidence, Degree, Time Course, Treatment, and SymptomsJournal of Clinical Oncology, 2009
- Long-Term Management of Breast Cancer-Related Lymphedema after Intensive Decongestive PhysiotherapyBreast Cancer Research and Treatment, 2006
- Predictive Factors of Response to Intensive Decongestive Physiotherapy in Upper Limb Lymphedema After Breast Cancer Treatment: a Cohort StudyBreast Cancer Research and Treatment, 2006
- The prevalence of arm oedema following treatment for breast cancerQJM: An International Journal of Medicine, 1996